Ovarian Cancer
‘Electronic nose’ accurately detects ovarian, pancreatic cancers
An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.
VIDEO: Mirvetuximab plus bevacizumab demonstrates 'impressive' results in ovarian cancer
In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about mirvetuximab, which “has generated considerable excitement and interest as an anti-ovarian cancer agent.”
Top in hem/onc: Ovarian cancer vaccine, liver cancer treatment
Recent data on gemogenovatucel-T showed the novel vaccine appeared to benefit women with BRCA wild-type and homologous recombination-proficient ovarian cancer.
Mirvetuximab soravtansine plus bevacizumab ‘highly active’ in ovarian cancer subset
Mirvetuximab soravtansine in combination with bevacizumab demonstrated antitumor activity with durable responses and favorable tolerability among women with high folate receptor-alpha recurrent ovarian cancer, according to study results.
Novel vaccine safe, effective in ovarian cancer subset
A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.
Adavosertib alone, in combination with olaparib effective in ovarian cancer subset
Adavosertib alone and in combination with olaparib demonstrated efficacy among women with poly(ADP-ribose) polymerase (PARP) inhibitor-resistant ovarian cancer, according to study results presented during the virtual ASCO Annual Meeting.
Bilateral oophorectomy increases risk for severe carpal tunnel syndrome
Premenopausal women who underwent bilateral oophorectomy had a higher risk for severe carpal tunnel syndrome compared with women who did not have the procedure, according to a study published in Menopause.
FDA grants breakthrough therapy designation to combination for recurrent ovarian cancer
The FDA granted breakthrough therapy designation to VS-6766 with defactinib for treatment of recurrent low-grade serous ovarian cancer, according to the agents’ manufacturer.
Atezolizumab regimen fails to extend PFS in newly diagnosed ovarian cancer
The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology.
Researcher develops novel sensor for early detection of ovarian cancer
Mijin Kim, PhD, has been selected to receive a 2021 Marie-Josée Kravis Women in Science Endeavor fellowship grant for her work on a novel sensor technology designed for early detection of ovarian cancer.